UK markets close in 2 hours 46 minutes

  • FTSE 100

    6,538.37
    -113.59 (-1.71%)
     

  • FTSE 250

    20,987.10
    -211.02 (-1.00%)
     

  • AIM

    1,183.16
    -8.70 (-0.73%)
     

  • GBP/EUR

    1.1500
    +0.0002 (+0.02%)
     

  • GBP/USD

    1.3945
    -0.0068 (-0.49%)
     

  • BTC-GBP

    33,267.47
    -3,081.46 (-8.48%)
     

  • CMC Crypto 200

    925.73
    -7.41 (-0.79%)
     

  • S&P 500

    3,829.34
    -96.09 (-2.45%)
     

  • DOW

    31,402.01
    -559.85 (-1.75%)
     

  • CRUDE OIL

    62.16
    -1.37 (-2.16%)
     

  • GOLD FUTURES

    1,760.10
    -15.30 (-0.86%)
     

  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     

  • HANG SENG

    28,980.21
    -1,093.96 (-3.64%)
     

  • DAX

    13,798.39
    -80.94 (-0.58%)
     

  • CAC 40

    5,721.96
    -61.93 (-1.07%)
     
Budget 2021:

Targeted tax rises won't derail COVID recovery, chancellor told

Corporation tax, capital gains tax, wealth tax, and land value tax rises would make a 'negligible impact' on GDP growth

DAVOS 2021: Americans 'no less happy' despite coronavirus crisis

Tom Belger
·Finance and policy reporter
·2-min read
A man carries his girlfriend while playing in the snow on Clapham Common, London, as parts of the UK and Ireland woke up to snow and ice on Sunday morning.
A couple in the snow in Britain as studies suggest little change in aggregate happiness levels despite the COVID-19 crisis. Photo: PA.

Happiness levels among much of the US public quickly returned to normal after the initial shock of the coronavirus crisis, according to an academic.

Professor Tali Sharot, a cognitive neuroscientist at University College London (UCL) made the bold claim at a panel event at the virtual Davos Agenda 2021 summit on Monday.

A team at UCL surveyed 1,145 Americans in 30 states last year. Sharot said they found a “significant decrease” in happiness and higher stress levels in the early stages of the pandemic’s spread.

But a follow-up survey found happiness and stress levels went back to prior levels within a month, in findings she called “incredible.”

READ MORE: China's Xi Jinping outlines four-point plan to battle threat to globalisation

Participants reported anxiety falling and a greater sense of control over time, with greater optimism about their own lives and happiness levels.

“This suggests that humans adapt to threats by maintaining positive and protective biases while reducing negative perceptions and emotions,” wrote Laura K. Globig, one of the researchers involved, in a summary of the research last year.

Sharot told the panel the happiest participants were those who did feel agency over their lives, and urged policymakers to look at ways to boost the public’s sense of agency. She highlighted some US school districts where choice over sending children to school had been left with parents as an example.

READ MORE: AstraZeneca CEO criticises 'me first' approach to COVID

But she said a “significant minority” of people were struggling with the pandemic. The study was also concluded by mid-2020, when not all the health, social and economic impacts of the pandemic would have been felt.

The study also found the number of COVID-19 cases and deaths in their state had no discernible impact on respondents’ wellbeing.

WEF’S annual meeting of global business, political and civil society leaders has been postponed to May and moved from Davos, Switzerland, to Singapore because of the pandemic.

The move led to the launch of this week’s additional ‘Agenda’ event in the run-up to the in-person summit, with more than 100 virtual sessions including heads of state and CEOs of global companies.

WATCH: How do world leaders get invited to Davos?

Latest stories

  • US consumers rebound to boost spending 2.4% as income jumps

    Bouncing back from months of retrenchment, America's consumers stepped up their spending by a solid 2.4% in January in a sign that the economy may be making a tentative recovery from the pandemic recession. Friday’s report from the Commerce Department also showed that personal incomes, which provide the fuel for spending, jumped 10% last month, boosted by cash payments most Americans received from the government. The January spending increase followed two straight monthly spending drops that had raised concerns that consumers, who power most of the economy, were hunkered down, too anxious to travel, shop and spend.

  • Pritam Singh asks for updates on Keppel O&M and FAS corruption probes

    Leader of the Opposition Pritam Singh has asked the government to give an update into two separate corruption probes into Keppel Offshore and Marine, and the Football Association of Singapore (FAS) and two local football clubs.

  • India exits recession with 0.4 percent quarterly growth

    India's economy grew 0.4 percent year-on-year in the final quarter of 2020, official data showed Friday, ending its first recession since independence as easing coronavirus restrictions sparked a modest recovery.

  • Here's What The Coronavirus R Rate Is Near You

    Official figures estimate the UK-wide reproduction number is between 0.6 and 0.9.

  • Better Buy: MercadoLibre vs. Alibaba

    MercadoLibre (NASDAQ: MELI) and Alibaba (NYSE: BABA) are two of the world's largest e-commerce companies. MercadoLibre, founded in Argentina in 1999, is Latin America's leading e-commerce player with a presence in 18 countries. Alibaba launched the same year and has become China's top e-commerce and cloud services company.

  • The Europe biofilms treatment market is expected to reach US$ 833.61 million by 2027 from US$ 454.60 million in 2019

    The market is estimated to grow with a CAGR of 7. 9% from 2020 to 2027. The growth of this market is driven by the rising prevalence of diabetes and associated illnesses, and growing incidence of pressure ulcers and traumatic wounds.New York, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Biofilms Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product ; Wound ; End User ; and Country" - https://www.reportlinker.com/p06004154/?utm_source=GNW However, multi-drugs resistance problem associated with biofilms treatment is restraining the growth of the market.The prevalence of diabetes and associated health conditions are increasing significantly.As per the International Diabetes Federation, ~425 million people are affected by diabetes globally.However, more than 58 million people live in Europe; by 2045, the number is expected to rise to 66.7 million. As per estimates, there were nearly 7,476,800 cases of diabetes in Germany during 2017. Approximately 15 % of diabetic patients in Germany are diagnosed with diabetic foot ulcers at least once in their lifetime, resulting in nearly 50,000 amputations annually. Moreover, ~230,000 new cases of diabetic foot ulcers are recorded in Germany every year. The country has an established nationwide accreditation system for diabetic foot clinics (DFCs). In Germany, a certification procedure is used for hospital departments that specialize in diabetic foot care. The “Diabetic Foot” of the German Diabetes Society (DDG) provides certification to hospitals, outpatient clinics, and ambulatory practices for inpatient and outpatient treatment of diabetic foot syndrome. As per National Health Survey (UK) estimates, around 10% or ~ 45,000 diabetic patients suffer from foot ulcers at some point in their lives. Over 7,000 amputations related to diabetes have been reported in the UK annually. This figure infers that ~200,000 diabetes patients with foot ulcers may not be alive in 5 years, and more than 5,500 patients of amputations related to diabetic have less than five years to live. As per NHS, it is estimated that in 2014–2015, the annual cost of diabetic foot disease treatment to the NHS in England was projected to be around US$ 1.21 billion (i.e., £1 billion), along with the personal or social costs of reduced mobility and sickness absence. Hence, the rising prevalence of diabetes and associated illnesses is anticipated to drive the Europe biofilms treatment market during the forecast period.The European economy is hindering due to the exponential growth of COVID-19 cases in the region.Spain, Italy, Germany, France, and the UK are among the most-affected European countries.The COVID-19 outbreak has been declared by WHO as a Public Health Emergency of International Concern, according to the International Health Regulation.The majority of the deaths were registered in these countries.Therefore, governments of various countries are implementing lockdown to control the spread of the novel coronavirus.The outbreak is restricting the medical services for different health conditions, and majority of healthcare services are offered only for COVID-19 infected people.For the other health conditions, the use of telemedicine and digital healthcare has increased significantly. However, the services for chronic wound care are reduced dramatically. Various events for wound care management, such as conferences and awareness campaigns, have also been postponed. Furthermore, the trade for wound care management has been reduced for the time being, which has resulted in a loss for various companies.Based on product, the Europe biofilms treatment market is segmented into debridement equipment, gauzes and dressings, grafts and matrices, and others. The gauzes and dressings segment held the largest share of the market in 2019, and the same segment is anticipated to register the highest CAGR in the market during 2020–2027.The Europe biofilms treatment market, based on wound, is segmented into traumatic and surgical wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and others. In 2019, the traumatic and surgical wounds segment held the largest share of the market; the same segment is anticipated to register the highest CAGR in the market during the forecast period.By end user, the Europe biofilms treatment market is segmented into hospitals, home care settings, and others. The hospitals segment held the largest market share in 2019 and is anticipated to register the highest CAGR in the market from 2020 to 2027.A few of the primary and secondary sources referred to while preparing the report on the Europe biofilms treatment market are the German Diabetes Society (DDG), National Health Survey (UK), and European Wound Management Association (EWMA).Read the full report: https://www.reportlinker.com/p06004154/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Businesswoman considers appeal after losing big-money court battle with Barclays

    Amanda Staveley complained about the behaviour of bank bosses when negotiating investment deals during the 2008 financial crisis.

  • Delisting of Certificates

    Nordea Bank Abp, as the issuer, has determined to delist below certificates due to low net asset value (NAV). The instruments will be delisted end of trading 2021-03-12. ISIN DK0060877363 DK0060919975 DK0061199213 DK0061201803 DK0061214970 DK0061255817 Attachment Delisting low NAV DK 20210312

  • Karolinska Development appoints Johan Dighed as Deputy CEO

    STOCKHOLM, SWEDEN – February 26, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that Johan Dighed has been appointed as Deputy CEO. He takes up the position immediately and will, in addition to his new duties, continue to hold his current role as the company's General Counsel. Johan Dighed was appointed as General Counsel at Karolinska Development in May 2020. He has a background from SEB, one of the leading Nordic banks, where he held a number of positions in the Division for Large Corporates and Financial Institutions, inter alia as Head of Legal at SEB:s German subsidiary SEB AG. Prior to that, he worked at the international law firm Baker & McKenzie and in the Swedish judiciary. “I am pleased that Johan Dighed has accepted the appointment as Deputy CEO. In his new and expanded role, we will be able to benefit even more from his solid business skills, strong leadership and experience in financing issues,” comments Karolinska Development's CEO, Viktor Drvota. For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders. Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success. Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases. The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network. For more information, please visit www.karolinskadevelopment.com Attachment KD PR vice vd 2021-02-26 ENG

  • No 10 defends Civil Service after senior aide says system ‘arrogant and remote’

    Baroness Finn, a key ally of Michael Gove, made the comments in an opinion article in the press.

  • CEO of Canada Pension Resigns After Vaccine Trip

    (Bloomberg) -- Mark Machin resigned as head of Canada Pension Plan Investment Board after he went to the United Arab Emirates and received a Covid-19 vaccine, defying guidance from Justin Trudeau’s government to avoid international travel.“After discussions last evening with the board, Mr. Machin tendered his resignation and it has been accepted,” CPPIB said in a written statement Friday morning. John Graham was named to replace him as chief executive officer.The office of Finance Minister Chrystia Freeland criticized Machin after the Wall Street Journal revealed the trip Thursday evening. The northern nation is still struggling to ramp up its own immunization campaign against the virus.“While the CPPIB is an independent organization, this is very troubling,” Katherine Cuplinskas, a spokeswoman for Freeland, said by email. “The federal government has been clear with Canadians that now is not the time to travel abroad.”The finance department was unaware of Machin’s trip, Cuplinskas said, referring further questions to the CPPIB.Despite securing more doses per capita than any other nation, Canada has administered enough shots to vaccinate just 4.5% of its population one time, compared with 29% in the U.K. and 20.6% in the U.S., according to Bloomberg’s vaccine tracker. That’s because Canada has to import the vaccines, and shipments have lagged.Recent public opinion has turned against officials who defy the government’s pleas to not leave the country: Rod Phillips, Ontario’s finance minister, was forced to resign on Dec. 31 after it was revealed he took a Caribbean vacation at a time when many businesses in the provinces were ordered to shut their doors to contain the virus.With vaccine deliveries now accelerating after delays caused in part by export controls in the European Union, Trudeau maintains that every Canadian will be inoculated by the end of September.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Global Oil and Gas Automation Solutions Market Report 2021-2025 - Market is Poised to Grow by $1.73 Billion - ResearchAndMarkets.com

    The "Global Automation Solutions Market in the Oil and Gas Industry 2021-2025" report has been added to ResearchAndMarkets.com's offering.

  • Global Eubiotics Market Anticipated to Reach $7.74 Billion by 2025 with Chr. Hansen, Koninklijke DSM., Kemin Industries, and BASF are Increasing Their Investments

    Dublin, Feb. 26, 2021 (GLOBE NEWSWIRE) -- The "Global Eubiotics Market: Focus on Offering Type (Probiotics, Prebiotics, Organic Acids), Applications (Gut Health, Immunity), Livestock Type (Swine, Poultry, Aquaculture) and End User - Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering. Global Eubiotics Market Anticipated to Reach $7.74 Billion by 2025 The market report includes several drivers that are influencing the changing demand for and dynamics of the eubiotics industry. The eubiotics market has undergone significant and dynamic changes in the past five years, specifically with the introduction of new and advanced solutions to improve animal health and well-being. With the increase in the world population leading to a rise in the global demand for meat food and the global prohibition on the usage of antibiotics growth promoters, livestock growers are increasingly adopting eubiotics products and ingredients to increase the yield and productivity of animals. The utilization of eubiotics as an animal feed has resulted in promoting the growth and maintaining animal health by managing the gut health and reduction in the proliferation of the undesirable pathogenic bacteria. As a result, the eubiotics market is anticipated to progress due to the ever-growing affinity for more convenient animal feed solutions than the traditional methods. Eubiotics market encompasses a wide array of offerings, including probiotics, prebiotics, organic acids, and essential oils. The probiotics offering type comprises a board range of bacterial strain including Lactobacilli, Bifidobacteria, Streptococcus Thermophilus, and others. Prebiotics offering type consists of Fructo-Oligosaccharides, Galacto-Oligosaccharides, and Mannan-Oligosaccharide that are offered by different companies present in the market. The organic acids section of the offering type consists of formic acid, lactic acid, fumaric acid propionic acid, and acetic acid. These offerings have applications in the management of gut health, immunity, and yield, among others. The presence of these probiotics, prebiotics, organic acids, and essential oils in the market has led to an exponential growth of the eubiotics market. High growth in the market is expected to be driven by the increasing consumption and demand for meat, growing livestock diseases, and ban on the utilization of antibiotics growth promoters. Governments of developed as well as developing countries have also taken several initiatives to promote eubiotics, especially after the ban on antibodies growth promoters. Moreover, the increasing demand for and consumption of the meat and meat-based products is also expected to drive the market in the future. Competitive Landscape The exponential utilization of advanced solutions in the eubiotics market has created opportunities for companies to adopt strategies such as collaborations, joint ventures, product launches, and developments and partnerships. The established companies in the eubiotics market are focusing more on business expansions and on finding ways to improve the existing techniques. Moreover, product launch activities have increased in the market during the last three years. Presently, the big four eubiotics companies, namely Chr. Hansen Holding A/S, Koninklijke DSM N.V., Kemin Industries, Inc., and BASF, are constantly increasing their investment in animal health improvement, by acquiring or collaborating with other companies. Several other companies, such as Anpario plc., Novus International Inc., Lallemand, Inc, and LESAFFRE, have launched different products to compete with the market-dominant players. The wide-spread adoption of advanced feed solutions is essential for linking the gap to improve animal health effectively. Key Questions Answered in this Report: What is the estimated global eubiotics market size in terms of value during the period 2019-2025?What is the expected future scenario and revenue to be generated by different types of eubiotics offerings, including probiotics, prebiotics, organic acid, and essential oils?What is the expected future scenario and revenue to be generated by the application segments for eubiotics, including gut health, immunity, and yield, among others?What is the expected future scenario and revenue to be generated by eubiotics in different types of forms, including solid or dry and liquid?What is the expected future scenario and revenue to be generated by eubiotics in different livestock types, including poultry, pig, ruminants, and aquaculture, among others?What is the expected future scenario and revenue to be generated by eubiotics in different end-user types, including humans and animals?What is the expected future scenario and revenue to be generated by eubiotics in different packaging types, including stand-up pouches/portion control and bulk packaging?What is the competitive strength of the key players in the eubiotics market on the basis of the analysis of their recent developments, product offerings, and regional presence?What are the emerging trends in the global eubiotics market?What is the funding and investment landscape in the global eubiotics market?What are the dynamics of the global eubiotics market including market drivers, restraints, and opportunities?What is the SWOT analysis for leading companies in the eubiotics market? Key Topics Covered: 1 Market Dynamics1.1 Overview1.2 Impact Analysis1.3 Market Drivers1.3.1 Increase in Consumption and Production of Meat and Meat-Based Products1.3.2 Supplanting Antibiotic Growth Promoters (AGPs) With Eubiotics1.3.3 Rapid Increases in the Livestock Disease1.4 Market Restraints1.4.1 Complexity in Trading due to Stringent Government Policies1.4.2 Lack of Sufficient Scientific Evidence1.5 Market Opportunities1.5.1 Rapid Investment to Enhance Animal Nutrition1.5.2 Opportunity to Invest on Consumer Awareness Amid COVID-19 2 Competitive Landscape2.1 Key Strategies and Developments2.1.1 Business Expansions and Contracts2.1.2 New Product Launches and Development2.1.3 Mergers and Acquisitions2.1.4 Partnerships, Collaborations, and Joint Ventures2.1.5 Others (Awards and Recognitions)2.2 Competitive Benchmarking of Key Eubiotics Companies 3 Industry Analysis3.1 Supply Chain Analysis3.2 Market Trends in the Eubiotics Market3.2.1 Shift Towards Natural Functional Ingredients3.2.2 Brand Differentiation Through Innovative Packaging3.2.3 Outbreak of Corona Pandemic Arising Immunity Concerns in Consumers3.2.4 Shift of Animal Husbandry Towards Efficient and Targeted Investments3.3 Impact of COVID-19 on Eubiotics Market3.3.1 Consumer Perception3.3.2 Government Regulation and Impact on Supply Chain3.3.3 The Way Forward for the Nutrition and Supplement Industry3.4 Patent Analysis3.4.1 Patent Analysis (by Status)3.4.2 Patent Analysis (by Applicant Profile)3.4.3 Patent Analysis (by Product Type)3.4.4 Patent Analysis (by Application)3.5 Investment and Funding Landscape 4 Global Eubiotics Market (by Offering Type)4.1 Market Overview4.2 Probiotics4.2.1 Lactobacilli4.2.2 Bifidobacterium4.2.3 Streptococcus Thermophilus4.2.4 Other Probiotics4.3 Prebiotics4.3.1 Inulin4.3.2 Fructo-Oligosaccharides4.3.3 Galacto-Oligosaccharides4.3.4 Mannan-Oligosaccharides4.4 Organic Acids4.4.1 Formic Acid4.4.2 Lactic Acid4.4.3 Fumaric Acid4.4.4 Propionic Acid4.4.5 Others4.5 Essential oils 5 Global Eubiotics Market (by Application)5.1 Market Overview5.2 Gut Health5.3 Immunity5.4 Yield Management5.5 Others 6 Global Eubiotics Market (by Livestock)6.1 Market Overview6.2 Swine6.3 Poultry6.4 Ruminants6.5 Aquaculture6.6 Other Livestock 7 Global Eubiotics Market (by Form)7.1 Market Overview7.2 Solid or Dry Form7.3 Liquid Form 8 Global Eubiotics Market (by End User)8.1 Market Overview8.2 Humans8.3 Animals8.3.1 Industrial Livestock8.3.2 Domesticated Animals 9 Global Eubiotics Market (by Packaging Type)9.1 Market Overview9.2 Stand-up Pouches/Portion Control9.3 Bulk Packaging9.3.1 Packet Packaging9.3.2 Bucket Packaging 10 Global Eubiotics Market (by Region)10.1 Market Overview10.2 North America10.3 South America10.4 U.K.10.5 China10.6 Europe10.7 Asia-Pacific & Japan10.8 Middle East and Africa 11 Company Profiles11.1 Company Overview11.2 Role in the Global Eubiotics Market11.3 Financials11.4 SWOT Analysis ADDCON GmbHAnpario plc.Archer Daniels MidlandBASF SEBEHN MEYERBENEO GmbHBioGaia ABBluestar Adisseo CoCalpis Co., Ltd.Cargill, Inc.Chr. Hansen Holding A/SDuPont de Nemours, Inc.Kemin Industries, Inc.Koninklijke DSM N.V.LALLEMAND Inc.LesaffreMSPrebiotics Inc.Neospark Drugs and Chemicals Private LimitedNovozymes A/SNovus International, Inc.Roquette FreresYara International ASA For more information about this report visit https://www.researchandmarkets.com/r/guri8b CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • U.S. Treasuries' selloff give European stocks an edge

    The selloff in U.S. Treasuries may finally give the bourses of Frankfurt, Paris or Milan a decisive edge for 2021 after five straight years of underperformance against Wall Street. What has changed from the previous years is that the 10-year U.S. yield, at roughly 1.5%, now matches the dividend yield of the S&P 500. That means a risk-free U.S. government bond yields as much as the average Wall Street stock's dividend.

  • Global Bond Rout Eases; Dollar Extends Advance: Markets Wrap

    (Bloomberg) -- Global bonds steadied on Friday as markets returned to firmer footing at the end of a week that saw the steepest decline in the Nasdaq 100 since the pandemic meltdown.Markets stabilized after central banks from Asia to Europe moved to calm a panic that had sent U.S. government bond yields to their highest level in a year. That triggered a loss of almost $900 billion this week in the value of the tech-heavy Nasdaq, the biggest since March.“If U.S. rates stabilize at these levels, which they appear to be, then equities will find calm,” said Nema Ramkhelawan-Bhana, a strategist at Rand Merchant Bank in Johannesburg. Fears that central banks withdraw support too fast may be overdone “given persistent rhetoric, with the Fed holding firm on its accommodation,” she said.Contracts on the Nasdaq 100 and S&P 500 fluctuated before turning modestly higher, suggesting a reprieve may be in store for stocks when U.S. markets open. The 10-year Treasury yield fell back below 1.5% after trading as high as 1.6% Thursday, while the dollar extended a rally to head for its best week since January.Investors are getting increasingly worried that accelerating inflation could trigger a pullback in monetary policy support that has fueled gains in risk assets amid the pandemic. Federal Reserve officials so far say surging Treasury yields reflect optimism and have stressed that the central bank has no plans to tighten policy prematurely.What Investors Are Watching After the Spike in Treasury YieldsYields on core European bonds ticked lower, and the benchmark Stoxx Europe 600 slumped more than 1% led, by cyclical shares.Elsewhere, oil retreated from its the highest in more than a year as traders mulled depleting global inventories. Bitcoin headed toward $45,000.Some key events to watch this week:Finance ministers and central bankers from the Group of 20 will meet virtually Friday. U.S. Treasury Secretary Janet Yellen will be among the attendees.These are some of the main moves in markets:StocksS&P 500 futures rose 0.1% by 8:32 a.m. in New York.Nasdaq 100 futures gained 0.5%.The Stoxx Europe 600 index dropped 1.1%.The MSCI Asia Pacific index declined 3.5%.The MSCI Emerging Markets index retreated 3%.CurrenciesThe Bloomberg Dollar Spot Index rose 0.4%.The euro was 0.5% lower at $1.2114.The British pound fell 0.7% to $1.3919.The Japanese yen slipped 0.1% to 106.35 per dollar.BondsThe yield on 10-year Treasuries dipped five basis points to 1.48%.Germany’s 10-year yield dropped three basis points to -0.26%.The yield on U.K. 10-year bonds rose two basis points to 0.8%CommoditiesWest Texas Intermediate crude fell 2.1% to $62.23 a barrel.Gold fell 0.6% to $1,760 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Botswana’s former president defends shoot-to-kill policy for poaching

    Ian Khama says shoot-to-kill is not shoot-on-sight, and says poachers should be warned of the risks they face targeting Botswana’s wildlife

  • Barca boss Koeman calls on others to help Messi

    Ronald Koeman called on Barcelona's players to step up and reduce the club's reliance on Lionel Messi for goals ahead of Saturday's La Liga trip to Sevilla. Messi, 33, has scored 18 times in the league this season with Antoine Griezmann the next highest scorer on six, and once again scored the opening two goals in Wednesday's league victory over Elche.

  • EMEA Access Control Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Component and Application

    The EMEA access control market was valued at US$ 2,849. 4 million in 2019 and is projected to reach US$ 8,327. 5 million by 2027; it is expected to grow at a CAGR of 14. 0% from 2020 to 2027. Presently, the access control solutions are increasingly being integrated for including other services and systems.New York, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "EMEA Access Control Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Component and Application" - https://www.reportlinker.com/p06004149/?utm_source=GNW Further, increase in building automation and smart homes is opportunistic for the market.Several companies, including Gemalto, Suprema Inc., and ATOS, are expanding and exploring ways for authenticating an individual using biometric-related information. Several hardware and software providers are teaming up to offer enhanced access control systems. For instance, Suprema Inc. formed new facility with the launch of Suprema Europe SARL to expand their presence and customer reach in the France market. Also, Allegion Middle East introduced their comprehensive portfolio of access control product to the UAE and across the Middle East countries. Further, Vanderbilt and 6SS formed partnership in the Middle East & Africa region to provide training and strengthen their product offering for market with high-quality certification.Moreover, several players are investing into innovation, research and development activities. Recently, dormakaba Group introduced new Keyscan Aurora 1.0.21 access-control management software to manage the flow and security efficiently through a building. Further, rise in number of SMEs adopting security systems has created growth avenues, especially in the developing economies of the world. Also, growing demand for the cloud technology in businesses, owing to remote working and enormous data management, is augmenting the market growth. For instance, Atos introduced Evidian—a cloud-based Identity-as-a-Service—for the enterprises to securely govern digital identities with a subscription-based pricing model.Honeywell Security Group; Siemens Building Technologies; ASSA ABLOY AB; ATG Access Ltd; Johnson Controls International plc; AMAG Technology, Inc.; Schneider Electric SE; Gallagher Group Ltd.; and Identiv, Inc. are among the key EMEA access control market players profiled in this research study.Impact of COVID-19 Pandemic on EMEA Access Control MarketThe COVID-19 outbreak, which began in Wuhan, China, in December 2019, has spread across the globe.It has badly affected China, Italy, Iran, Spain, the Republic of Korea, France, Germany, and the US in terms of confirmed positive cases and reported deaths as of March 2020.The COVID-19 outbreak has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The overall market breakdown due to COVID-19 is also affecting the growth of the EMEA access control market due to factory shutdowns, disrupted supply chain, and downturned global economy.Overall size of the EMEA access control market has been derived in accordance to primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants who typically take part in such a process include industry experts, such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants, such as valuation experts, research analysts, and key opinion leaders specializing in the access control market.Read the full report: https://www.reportlinker.com/p06004149/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • World Particle Board Market Analysis, Forecast, Size, Trends and Insights Report 2021 - ResearchAndMarkets.com

    The "World - Particle Board - Market Analysis, Forecast, Size, Trends and Insights. Update: COVID-19 Impact" report has been added to ResearchAndMarkets.com's offering.

  • John Boehner tells Ted Cruz to go ‘f*** himself’ in unscripted audiobook recording, report says

    Former House speaker previously referred to Texas senator as ‘Lucifer in the flesh’